Luciano J Costa

List of Publications by Year in Descending Order

153 papers	3,441 citations	29 h-index	57 g-index
164 ext. papers	4,501 ext. citations	4.2 avg, IF	5.01 L-index

#	Paper	IF	Citations
153	Real-World Applicability of Commercial Chimeric Antigen Receptor T Cell Therapy Among Older Adults with Relapsed and/or Refractory Multiple Myeloma.. *American Journal of Hematology*, **2022**,	7.1	1
152	How I treat triple-class refractory multiple myeloma.. *British Journal of Haematology*, **2022**,	4.5	1
151	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.. *Journal of Clinical Oncology*, **2021**, JCO2101935	2.2	13
150	Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study. *Blood*, **2021**, 138, 157-157	2.2	8
149	Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. *Leukemia*, **2021**,	10.7	3
148	Associa Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients. *Hematology, Transfusion and Cell Therapy*, **2021**, 43 Suppl 2, S30-S34	1.6	0
147	High Dose Fractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (mHyperCVAD) Is an Active Regimen in Heavily Pretreated Relapsed/Refractory Multiple Myeloma, Enabling Access to Experimental Therapies. *Blood*, **2021**, 138, 3784-3784	2.2	2
146	Maximum-tolerated dose of lomustine used in combination with etoposide and cyclophosphamide in conditioning regimen for hematopoietic stem cell transplantation in lymphoma patients. *Bone Marrow Transplantation*, **2021**,	4.4	
145	Managing Multiple Myeloma in Older Adults Using Real World Evidence and Clinical Integration of a Geriatric Assessment Tool in Clinical Practice. *Blood*, **2021**, 138, 5019-5019	2.2	
144	Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. *Blood*, **2021**, 138, 158-158	2.2	9
143	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. *Lancet Oncology, The*, **2021**, 22, e105-e118	21.7	32
142	Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma-Reply. *JAMA Oncology*, **2021**, 7, 635-636	13.4	
141	Impact of insurance status on the survival of younger patients diagnosed with acute promyelocytic leukemia in the United States. *Cancer*, **2021**, 127, 2966-2973	6.4	0
140	Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population-based study. *American Journal of Hematology*, **2021**, 96, E265-E268	7.1	1
139	Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy. *Lancet Haematology,the*, **2021**, 8, e386-e387	14.6	2
138	Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma. *British Journal of Haematology*, **2021**, 195, e113-e116	4.5	1
137	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. *Leukemia*, **2021**, 35, 18-30	10.7	29

136	Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis. *Journal of Geriatric Oncology*, **2021**, 12, 256-261	3.6	1
135	Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy. *Transplantation and Cellular Therapy*, **2021**, 27, 55.e1-55.e7		1
134	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. *American Journal of Hematology*, **2021**, 96, E5-E8	7.1	9
133	Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. *Transplantation and Cellular Therapy*, **2021**, 27, 264.e1-264.e7		6
132	Leveraging minimal residual disease to reassess autologous hematopoietic cell transplantation in multiple myeloma. *Advances in Cell and Gene Therapy*, **2021**, 4, e97	1.2	
131	Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation. *Bone Marrow Transplantation*, **2021**, 56, 1364-1372	4.4	2
130	Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. *Blood Advances*, **2021**, 5, 1092-1096	7.8	4
129	Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation. *American Journal of Hematology*, **2021**, 96, E396-E398	7.1	0
128	Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. *Expert Review of Hematology*, **2021**, 1-16	2.8	0
127	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. *BMC Cancer*, **2021**, 21, 993	4.8	1
126	Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. *Blood Advances*, **2021**, 5, 3748-3759	7.8	11
125	Reduction in Late Mortality Among Patients With Multiple Myeloma Treated With Autologous Peripheral Blood Stem Cell Transplantation-A Blood or Marrow Transplant Survivor Study Report. *Transplantation and Cellular Therapy*, **2021**, 27, 840.e1-840.e7		0
124	New regimens and directions in the management of newly diagnosed multiple myeloma. *American Journal of Hematology*, **2021**, 96, 367-378	7.1	4
123	Enrolment of racial minorities across 15 years of multiple myeloma randomised trials; calling on researchers to become agents of change. *Lancet Haematology,the*, **2020**, 7, e704-e706	14.6	2
122	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. *Blood*, **2020**, 136, 936-945	2.2	189
121	Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab?. *Cancer Medicine*, **2020**, 9, 5519-5525	4.8	6
120	Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 351-357	2	10
119	Impact of Autologous Hematopoetic Stem Cell Transplant (AHCT) on Measurable Residual Disease (MRD) By Next Generation Sequencing (NGS) in the Setting of Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Quadruplet Induction.. *Biology of Blood and Marrow Transplantation*, **2020**, 26, S24	4.7	2

118	Role of Neutrophil Lymphocyte Ratio [NLR] As a Biomarker of Frailty and Predictor of Survival Among Older Adults with Multiple Myeloma (MM). *Blood*, **2020**, 136, 6-6	2.2	
117	Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone. *Blood*, **2020**, 136, 4-5	2.2	2
116	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. *Blood*, **2020**, 136, 45-46	2.2	13
115	Defining and Managing High-Risk Multiple Myeloma: Current Concepts. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2020**, 18, 1730-1737	7.3	8
114	Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 798-804	4.7	22
113	Treatments for newly diagnosed multiple myeloma: when endurance is interrupted. *Lancet Oncology, The*, **2020**, 21, e540	21.7	1
112	Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis. *JAMA Oncology*, **2020**, 6, 1759-1765	13.4	34
111	Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. *Biology of Blood and Marrow Transplantation*, **2020**, 26, e7-e15	4.7	9
110	Up-front autologous hematopoietic stem cell transplantation (AHSCT) from a single Brazilian center. *Bone Marrow Transplantation*, **2020**, 55, 1181-1183	4.4	1
109	Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. *Bone Marrow Transplantation*, **2020**, 55, 1810-1816	4.4	21
108	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1744-1755	4.7	4
107	Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivors. *Leukemia Research*, **2019**, 82, 1-6	2.7	1
106	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. *Leukemia*, **2019**, 33, 2266-2275	10.7	188
105	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 73-85	4.7	25
104	Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. *New England Journal of Medicine*, **2019**, 381, 727-738	59.2	266
103	Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma. *British Journal of Haematology*, **2019**, 186, 807-819	4.5	6
102	First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial. *Blood*, **2019**, 134, 143-143	2.2	76
101	Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM). *Blood*, **2019**, 134, 860-860	2.2	57

100	Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 233-238	4.7	6
99	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. *Leukemia and Lymphoma*, **2019**, 60, 940-946	1.9	2
98	Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. *Leukemia and Lymphoma*, **2019**, 60, 894-903	1.9	7
97	LEAM versus CBV for conditioning in autologous hematopoietic stem cell transplantation for lymphoma. *Bone Marrow Transplantation*, **2019**, 54, 625-628	4.4	2
96	Incidence and outcomes of rare paediatric non-hodgkin lymphomas. *British Journal of Haematology*, **2019**, 184, 864-867	4.5	5
95	Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 909-913	4.7	27
94	Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1379-1385	4.7	11
93	R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. *British Journal of Haematology*, **2018**, 180, 534-544	4.5	48
92	Incidence and outcomes of paediatric myelodysplastic syndrome in the United States. *British Journal of Haematology*, **2018**, 180, 898-901	4.5	2
91	Second primary malignancy after multiple myeloma-population trends and cause-specific mortality. *British Journal of Haematology*, **2018**, 182, 513-520	4.5	14
90	Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant. *Bone Marrow Transplantation*, **2018**, 53, 1345-1348	4.4	2
89	Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara-Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT). *Blood*, **2018**, 132, 151-151	2.2	31
88	Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment. *Blood*, **2018**, 132, 3233-3233	2.2	5
87	Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies. *Blood*, **2018**, 132, 3303-3303	2.2	1
86	Temporal Trends in Early Mortality in Acute Promyelocytic Leukemia in the United States. *Blood*, **2018**, 132, 710-710	2.2	1
85	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. *Blood*, **2018**, 132, 2015-2015	2.2	7
84	Nonbiological Factors Affecting Outcomes in Adolescent and Young Adults with Lymphoma. *Blood*, **2018**, 132, 4857-4857	2.2	
83	Evaluation of Pre-Collection Factors and Collection Efficiency Leads to Strong Correlation between Predicted and Actual Peripheral Blood Stem Cell Collection Yields in Multiple Myeloma Patients: A Single Institution Experience. *Blood*, **2018**, 132, 3349-3349	2.2	

82	Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults. *American Journal of Hematology*, **2018**, 93, 238-245	7.1	5
81	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. *Journal of Clinical Oncology*, **2018**, 36, 859-866	2.2	100
80	Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow. *Leukemia Research*, **2018**, 74, 64-67	2.7	3
79	Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. *Cancer*, **2017**, 123, 3141-3149	6.4	38
78	Autologous and allogeneic progenitor cell mobilization **2017**, 45-52		0
77	C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. *Cancer*, **2017**, 123, 4411-4418	6.4	19
76	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 269-277	4.7	15
75	Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. *American Journal of Hematology*, **2017**, 92, 161-170	7.1	43
74	Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. *Blood Advances*, **2017**, 1, 282-287	7.8	164
73	Impact of marital status, insurance status, income, and race/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States. *Cancer*, **2016**, 122, 3183-3190	6.4	44
72	Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making. *American Journal of Hematology*, **2016**, 91, 1044-51	7.1	6
71	Reply to a note on the magnitude of hazard ratios. *Cancer*, **2016**, 122, 1299-300	6.4	
70	Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features. *Cancer Causes and Control*, **2016**, 27, 81-91	2.8	21
69	Expression of Epstein-Barr Virus in Cell of Classical Hodgkin's Lymphoma Tumor. *Blood*, **2016**, 128, 5358-5358	2.2	1
68	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1197-1205	4.7	12
67	Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. *Leukemia and Lymphoma*, **2016**, 57, 2827-2832	1.9	38
66	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1543-1551	4.7	34
65	Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. *Journal of Hematology and Oncology*, **2016**, 9, 71	22.4	17

64	Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2016**, 91, 101-8	7.1	16
63	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1746-53	4.7	39
62	Changes in the use of radiation therapy for early classical Hodgkin lymphoma in adolescents and young adults: implications for survival and second malignancies. *Leukemia and Lymphoma*, **2015**, 56, 2339-43	1.9	7
61	Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. *Leukemia and Lymphoma* , **2015**, 56, 3320-8	1.9	53
60	Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. *Leukemia and Lymphoma*, **2015**, 56, 645-9	1.9	23
59	Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma. *Cancer Control*, **2015**, 22, 87-94	2.2	5
58	Nonbiological factors affecting survival in younger patients with acute myeloid leukemia. *Cancer*, **2015**, 121, 3877-84	6.4	35
57	Fewer scans, better care. *Journal of Clinical Oncology*, **2015**, 33, 1624	2.2	1
56	Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 552-8	4.7	9
55	Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 701-6	4.7	51
54	Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM). *Blood*, **2015**, 126, 396-396	2.2	2
53	Pegfilgrastim 6 Mg Versus 12 Mg for Autologous Stem Cell Mobilization in Multiple Myeloma Patients: Efficacy, Safety, and Cost Analysis. *Blood*, **2015**, 126, 4306-4306	2.2	1
52	Demographic Differences Between Unselected Patients and Participants of Multiple Myeloma Clinical Trials in the US: A Threat to External Validity. *Blood*, **2015**, 126, 634-634	2.2	
51	Insurance Status, Marital Status and Income, but Not Race-Ethnicity Affect Outcomes of Younger Patients Diagnosed with Multiple Myeloma in the US. *Blood*, **2015**, 126, 633-633	2.2	
50	Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 295-308	4.7	218
49	Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1729-36	4.7	79
48	Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 89-97	4.7	99
47	Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1262-73	4.7	130

46	Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 222-8	4.7	29
45	Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 951-9	4.7	30
44	Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 402-408.e1	4.7	79
43	Early Mortality in Multiple Myeloma: Risk Factors and Impact on Population Outcomes. *Blood*, **2014**, 124, 1320-1320	2.2	4
42	Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation. *Blood*, **2014**, 124, 2447-2447	2.2	1
41	Disparities in Utilization of Autologous Hematopoietic Progenitor Cell Transplantation for Multiple Myeloma in the US. *Blood*, **2014**, 124, 557-557	2.2	
40	Induction Therapy with Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplantation for Systemic Light Chain Amyloidosis: Our Experience. *Blood*, **2014**, 124, 5907-5907	2.2	
39	Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. *Blood*, **2013**, 121, 4861-6	2.2	61
38	Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 1615-24	4.7	85
37	Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g). *Blood*, **2013**, 122, 1820-1820	2.2	14
36	Sphingolipids As a Novel Target For The Treatment Of Multiple Myeloma. *Blood*, **2013**, 122, 3163-3163	2.2	1
35	A Phase I/II Trial Of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) In Patients With Newly Diagnosed Multiple Myeloma: Final Results Of MTD Expansion Cohort. *Blood*, **2013**, 122, 3179-3179	2.2	11
34	Phase 1 Trial Of Carfilzomib + High Dose Melphalan Conditioning Regimen Prior To Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Relapsed Multiple Myeloma. *Blood*, **2013**, 122, 3329-3329	2.2	1
33	Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America. *Blood*, **2013**, 122, 768-768	2.2	
32	Changes In The Use Of Radiation Therapy Among Adolescents and Young Adults With Early Stage Classical Hodgkin Lymphoma: Implications For Survival and Risk Of Secondary Malignancies. *Blood*, **2013**, 122, 722-722	2.2	
31	Similar Dynamics Of Intra Apheresis Autologous CD34+ Recruitment and Collection Efficiency In Patients Undergoing Mobilization With Or Without Plerixafor. *Blood*, **2013**, 122, 904-904	2.2	
30	Population Outcomes Of Primary Mediastinal Large B-Cell Lymphoma In The Rituximab Era. *Blood*, **2013**, 122, 1743-1743	2.2	
29	Excessive Early Mortality Drives Poor Long Term Outcomes Among Older Patients With Classical Hodgkin Lymphoma: A Population Study. *Blood*, **2013**, 122, 1742-1742	2.2	

28	Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. *Transfusion*, **2012**, 52, 2375-81	2.9	24
27	Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange. *European Journal of Haematology*, **2012**, 89, 432-4	3.8	7
26	Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia. *Blood*, **2012**, 120, 3933-3933	2.2	2
25	Results From the Phase II Dose Expansion of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2012**, 120, 445-445	2.2	6
24	A phase I/II trial of cyclophosphamide, carfilzomib, thalidomide, and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma.. *Journal of Clinical Oncology*, **2012**, 30, 8010-8010	2.2	7
23	Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America. *Blood*, **2012**, 120, 813-813	2.2	
22	Trends in Survival of Patients with Burkitt Lymphoma Diagnosed in the USA: An Analysis of 3691 Cases. *Blood*, **2012**, 120, 761-761	2.2	
21	The Influence of Race and ADAMTS13 Status On Outcomes in Thrombotic Thrombocytopenic Purpura. *Blood*, **2012**, 120, 4638-4638	2.2	
20	Risk and Outcome of Non-Hodgkin Lymphoma Among Hodgkin Lymphoma Survivors: Analysis From the Surveillance, Epidemiology and End Results (SEER) Registry.. *Blood*, **2012**, 120, 2639-2639	2.2	
19	Trends in Utilization and Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) in the Upfront Management of Patients with Multiple Myeloma: A Cibmtr Analysis. *Blood*, **2012**, 120, 596-596	2.2	
18	Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. *Blood*, **2011**, 118, 282-8	2.2	476
17	Comparison Between Pegfilgrastim and Filgrastim-Based Autologous Hematopoietic Stem Cell Mobilization in the Setting of Patient Adapted (Just in Time) Plerixafor: Efficacy and Cost Analysis. *Blood*, **2011**, 118, 1921-1921	2.2	1
16	Preliminary Results of a Phase 2 Study of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma. *Blood*, **2011**, 118, 2940-2940	2.2	1
15	Potential Use of Sphingosine Kinase-2 Selective Inhibitors for the Treatment of Multiple Myeloma. *Blood*, **2011**, 118, 5105-5105	2.2	
14	Characterization of Pim Protein Kinases and Evaluation of Small Molecule Inhibitors in Multiple Myeloma. *Blood*, **2011**, 118, 2909-2909	2.2	
13	Regulation and Functional Role of Beta2-Adrenergic Receptor in Acute Myelogenous Leukemia. *Blood*, **2011**, 118, 2563-2563	2.2	
12	Proteomic Analysis of Plasma Exosome-Associated Proteins Reveals That Differences In Kappa:Lambda Ratios Predict Severe Acute Graft-Versus-Host Disease Early After Allogeneic Hematopoietic Stem Cell Transplantation.. *Blood*, **2010**, 116, 1278-1278	2.2	2
11	Most Patients with Core Binding Factor AML Require Hematopoietic Stem Cell Transplantation for Long-Term Survival: Long Term Follow-up of a Cohort of Unselected Patients.. *Blood*, **2010**, 116, 4560-4560	2.2	0

10	Dual Inhibition of mTOR and Pim Kinase Pathways Using Small Molecule Inhibitors Synergistically Kills Myeloid Leukemic Cells In Vitro and In Vivo.. *Blood*, **2010**, 116, 293-293	2.2	
9	Extended Use of Ciprofloxacin Markedly Decreases the Incidence of Severe BK Virus-Associated Hemorrhagic Cystitis In Allogeneic HSCT Recipients. *Blood*, **2010**, 116, 2317-2317	2.2	
8	Association of Age with Fluorescence In Situ Hybriditization (FISH) Abnormalities In Multiple Myeloma Patients Reveals Higher Rate of Igh Translocations Among Older Patients. *Blood*, **2010**, 116, 1913-1913	2.2	
7	Effects of Method of Peripheral Blood Hematopoietic Stem Cell Mobilization (G-CSF, G-CSF + Plerixafor, or Cyclophosphamide + G/GM-CSF) on Engraftment and Sustained Graft Function: Comparison Across Cohorts with Similar CD34+ Cell Dose. *Blood*, **2010**, 116, 2255-2255	2.2	
6	High-Dose Cyclophosphamide Is An Effective Salvage Therapy for High-Risk Multiple Myeloma Refractory to New Biological Agents. *Blood*, **2010**, 116, 5041-5041	2.2	
5	Race, Access to Care, and Outcome After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. *Blood*, **2010**, 116, 1509-1509	2.2	
4	Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. *Leukemia and Lymphoma*, **2009**, 50, 781-7	1.9	5
3	Cost-Effective Use of Plerixafor for Hematopoietic Stem Cells Mobilization: Development and Validation of a Decision-Making Algorithm.. *Blood*, **2009**, 114, 3216-3216	2.2	3
2	Excessive Rate of Late Infections and Treatment Related Mortality Associated with the Use of Alemtuzumab in Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Trial.. *Blood*, **2009**, 114, 2230-2230	2.2	
1	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. *Blood Cancer Discovery*,OF1-OF12	7	2